Mark Neumann - 10 Mar 2022 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Reporting relationship: EVP, Chief Commercial Officer
Issuer ticker: ITCI
Reported as of: 10 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Mar 2022, 16:13:45 UTC
Prior SEC filing: 25 Feb 2022
Next SEC filing: 08 Apr 2022
Source filing: View source filing
Reporting owner signature: /s/ Lawrence J. Hineline, Attorney-in-fact

Key filing fact

Mark Neumann filed Form 4 for Intra-Cellular Therapies, Inc. (ITCI) on 14 Mar 2022.

Key facts

This page summarizes Mark Neumann's Form 4 filing for Intra-Cellular Therapies, Inc. (ITCI).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 14 Mar 2022, 16:13.

Change

Previous filing in this sequence was filed on 25 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ITCI transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +17,916
Change %
Price: $0.000000
Shares after: 17,916
Date: 10 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,916
Exercise price: $56.73
Footnotes: F1

ITCI transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +22,034
Change %
Price: $0.000000
Shares after: 22,034
Date: 10 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,034
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On March 10, 2022, the reporting person was granted options to purchase 17,916 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of common stock.

Footnote F3

On March 10, 2022, the reporting person was granted 22,034 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.